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Summary. Factor V Leiden (FVL) leads to a sevenfold
increased risk of venous thrombosis and is present in 50% of
individuals from families referred because of unexplained
familial thrombophilia. We assessed the association of FVL
with venous thromboembolism (VTE) in 12 thrombophilic
families of symptomatic probands with FVL in a retro-
spective follow-up study. We screened 182 first- and second-
degree relatives of the 12 unrelated propositi for the FVL
mutation and the occurrence of VTE. The incidence rate of
VTE in carriers of FVL (0-56%/year) was about six times the
incidence for the Dutch population (0-1%/year). The
incidence rate in non-carriers also appeared to be higher
(0-15% per year). At the age of 50 years, the probability of
not being affected by VTE was reduced to 75% for carriers
and to 93% for non-carriers (P = 0-009). Identification of
carriers of FV Leiden may be worthwhile in young
symptomatic individuals and their relatives with a strong
positive family history of venous thromboembolism or a
history of recurrent venous thrombosis who may be at risk
(e.g. pregnancy, use of oral contraceptives). After adjust-
ment for prothrombin G20210A (present in two families),
even higher thrombotic incidence rates were found in
carriers and non-carriers of FVL. This makes the presence of
other unknown prothrombotic risk factors more probable in
these families.
Keywords: venous thromboembolism, factor V Leiden,
hypercoagulability, thrombophilia, activated protein C
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Venous thromboembolism is a major cause of morbidity
with an incidence of about one per 1000 per year
(Nordström et al, 1992; National Medical Registration of
the Foundation Information Centre for Health, 1996).
Predisposing factors can be either genetic or environmental.
Environmental risk factors include recent surgery, immobi-
lization, oral contraceptives, pregnancy and puerperium
(Nachman & Silverstein, 1993). Until 1993, a specific
genetic defect was identifled in a maximum of 10-15% of
affected subjects (Allaart & Briet, 1994). These defects
included deficiencies of the main Inhibitors of the clotting
System: protein C, protein S and anti-thrombin (Hirsh et al,
1986). Familial resistance to activated protein C (APC-
resistance), first described in 1990 (Dahlbäck et al, 1990), is
the most frequent genetic risk factor for thrombosis (Griffin
et al, 1993; Koster et al, 1993; Svensson & Dahlbäck, 1994;
Dahlbäck, 1995; Lane et al, 1996). In the large majorily of
cases, APC resistance is associated with a single point
mutation (1691 G to A Substitution) in the factor V gene
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that predicts the synthesis of a factor V molecule (Factor V
Leiden) that is not properly inactivated by activated protein
C (APC) (Bertina et al, 1994; Greengard et al, 1994;
Voorberg et al, 1994). In Caucasians, this mutation is
present in about 5% of healthy individuals (Rees et al, 1995;
Zivelin et al, 1997). Factor V Leiden leads to a sevenfold
increased risk of venous thrombosis (Rosendaal et al, 1995).
It is present in 20% of unselected, consecutive patients with
deep vein thrombosis and in 50% of individuals from
families referred because of unexplained familial thrombo-
philia (Bertina ei al, 1994; Zöller et al, 1994; Lane et al,
1996).
We demonstrated an earlier age of onset in a series of
selected patients from thrombophilic families with factor V
Leiden than in a panel of unselected patients with a first
venous thrombosis who turned out to be carriers of the
factor V Leiden mutation (Lensen et al, 1996). This suggests
a higher thrombotic tendency in members from selected
families than in consecutively diagnosed patients, even if
both carry the same or a similar molecular defect.
Important to clinicians is the question of what prophylactic
measures are advisable for patients and their relatives in
these selected thrombophilic families with factor V Leiden.
Before this question can be answered, the risk of thrombosis
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in these individuals needs lo be assessed. Therefore, we
studied 12 thrombophilic families with the factor V Leiden
mutation in which, next to the proband, at least two
persons had experienced thrombosis.
PATIENTS AND METHODS
Paüents and families. The 12 probands originate from a
larger panel of 28 patients who were referred to our centre
for diagnostic work-up for venous thrombophilia, i.e.
patients with a positive family history of venous thrombosis
(at least two symptomatic relatives in addition to the
proband) and who did not have deficiencies of protein C,
protein S or anti-thrombin. These 28 patients were screened
for the presence of the factor V Leiden mutation which was
detected in 12 patients. We invited the siblings, parents and
children of these 12 probands, äs well äs uncles and aunts of
the affected parental side, and, if these were carriers, their
children (first cousins of the proband) to participate. Family
members under 15 years of age were excluded for practical
purposes. Of the 12 probands, 182 first- and second-degree
family members (93%) participated in the study and 12 did
not, three members because they lived abroad and nine for
reasons unknown. In all cases of couples with factor V
Leiden-positive children, we verified from which parent the
mutant allele was transmitted by testing the other parent.
In 30 of these cases, none of the other parents who had
married into these pedigrees, carried the factor V Leiden
allele.
The 12 probands and their 182 family members were
seen by the same physician for venepuncture and interview;
risk factor Status was assessed by the Interviewer before
carrier Status was determined (except for the proband). A
standardized history was taken of the occurrence of deep
venous thrombosis (excluding superficial thrombophlebitis)
and pulmonary embolism, including the age at each
episode, the method of diagnosis, treatment and predispos-
ing circumstances. The history included occurrence of risk
factors in the past: surgery, hospital admission, immobiliza-
tion (period exceeding two weeks), plaster casts, malignan-
cies, pregnancies, postpartum periods and use of oral
contraceptives, hormonal replacement therapy or oral
anticoagulants. When a patient reported to have experi-
enced a thrombotic event, clinical information was gathered
for confirmation from the physician responsible for the
treatment of the patient. We counted äs venous thrombotic
events only those that had been diagnosed by physicians
(80% of deep venous thrombotic events were objectively
diagnosed, i.e. by ultrasound, venography, pulmonary
angiography or lung Ventilation perfusion scan; 20% were
not, mainly because of events occurring before objective
diagnostic techniques were available).
Laboratory methods. Blood samples were collected from the
antecubital vein into 0-106 mmol/1 trisodium citrate.
Plasma was prepared by centrifugation for 10 min at
2000g at room temperature and stored at — 70°C in
1-5 ml volumes. The mutation of the factor V gene was
detected with the use of amplification and restriction-
enzyme digestion. Normalized APC-sensitivity ratios were
measured äs described previously (de Ronde & Bertina,
1994). APC resistance was defined äs normalized APC-
sensitivity ratio of <0·84; carriers of factor V Leiden
usually have a normalized APC-sensitivity ratio of <0·71
(Bertina et al, 1994). We measured normalized APC-
sensitivity ratios in all relatives who were not treated with
oral anticoagulants (n = 166) and found a clear association
of factor V Leiden and a normalized APC-sensitivity ratio of
<0·71. We screened all individuals for deficiencies of
protein C, protein S, anti-thrombin and the 20210 G to A
prothrombin variant. These laboratory measurements were
carried out by one laboratory technician who had no
knowledge of the medical history.
Statistics. We analysed the lifetime risk of thrombosis by
Standard life-table techniques (Kaplan-Meier method). To
compare the two curves we used the logrank test, resulting
in a chi-square distribution with one degree of freedom. This
analysis of lifetime risk of thrombosis based on retrospective
data is valid under the assumption that there is no excess
mortality in these families. Absence of excess mortality for
factor V Leiden has been reported by Mari et al (1996) and
Hille et al (1997), and is analogous to other reports on the
absence of excess mortality in thrombophilic families with
deficiencies of anti-thrombin or protein C (Rosendaal et al,
1991; van Boven ei al, 1994; Allaart et al, 1995). We have
assessed occurrences of superficial thrombophlebitis (diag-
nosed by a physician), but we performed further analyses
without this type of venous thrombosis (because of
difficulties in the subjective diagnosis and for reasons of
comparability with other published studies). When neces-
sary, we also excluded second-degree relatives for compar-
ability with other studies.
We compared the incidence rates of first venous
thrombotic events in relatives with factor V Leiden (carriers)
and without factor V Leiden (non-carriers) of the 12
probands. We calculated these incidence rates by counting
patient-years of observation (follow-up Urne) and dividing
the number of events in each group by the total number of
patient-years of all the individuals in the group. Follow-up
for symptomatic individuals started at birth and ended at
the date of the first venous thrombosis. Follow-up for
asymptomatic individuals started at birth and ended at the
date of the interview. For all participants, follow-up was
complete. Incidence rates of recurrent venous thrombotic
events were computed äs the number of recurrences divided
by the total of follow-up time in symptomatic relatives
between the first event and the date of the recurrence or the
date of the interview, whichever came first.
We used Poisson regression analysis to study the role of
the putative risk factors: age (seven 10-year age groups
ranging from age 10-19 years to 70-79 years), sex,
heterozygosity for factor V Leiden, surgery (exposition
window: l year per Operation), immobilizalion longer
than 2 weeks (including hospital admissions and plaster
casts; exposition window: l year), obesity (body mass Index
> 25 kg/m2), smoking, pregnancy/post partum period
(exposition window set at l year) and use of oral contra-
ceptives (only for time periods lasting at least l month). As
the prothrombin G20210A variant was present in two
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families, we adjusted for this coagulation defect in order to




We studied 182 relatives of 12 probands with factor V
Leiden. Of these 182 family members, 91 were heterozygous
for the factor V Leiden mutation (44 men and 47 women;
median age 39 years). One relative was homozygous (62-
year-old man) and 90 relatives were non-carriers (46 men
and 44 women, median age 36 years).
Twenty-five (14%) of the 182 relatives were symptomatic.
Of the 92 factor V Leiden carriers (probands excluded), 20
(22%) had experienced one or more venous thrombotic
events in their lifetime (first event was a pulmonary
embolism in four carriers and a venous thrombosis in a
lower extremity in 16 carriers). Five of the 90 non-carriers
(6%) experienced a venous thrombotic event (first event was
a pulmonary embolism in three non-carriers and a deep
venous thrombosis in a lower extremity in two non-
carriers). Among carriers, the incidence of venous throm-
bosis was 0-56%/year (20 events on 3585 person-years),
which was 3-7-fold (95% CI 1-4-10-0) higher than the
incidence of 0-15%/year among non-carriers (five events on
3354 person-years). First event was a superficial throm-
bophlebitis in nine carriers and in one non-carrier.
We calculated the thrombosis-free survival by Kaplan-
Meier analysis (Fig 1). At the age of 50 years, the
probability of being free of deep venous thromboembolism
was reduced to 75% for heterozygotes; for non-carriers,
93% were still free of thrombosis at this age (P = 0-009).
These significant differences could not be explained by
different frequencies of other risk factors in the two groups.
Overall relative risk of carriers vs. non-carriers, äs
calculated by the Cox proportional hazards model, was
3-4 (95% CI 1-3-9-2). Interestingly, the symptomatic
fraction of first-degree family members with factor V Leiden
was significantly higher than the symptomatic fraction of
second-degree family members with factor V Leiden. Among
36 first-degree relatives carrying factor V Leiden, 17 (47%)
had experienced venous thrombosis, äs compared with three
(5%) among 56 second-degree relatives with factor V
Leiden. This is visualized in Fig 2, which shows the
thrombosis-free curves for the first-degree relatives only.
The incidence of first venous thrombosis in the 92
carriers of factor V Leiden (probands excluded) was 0-2%/
year up to age 24 years (vs. 0-05%/year in non-carriers).
Between 25 years and 45 years of age the incidence was
1-1%/year (vs. 0-3%/year in non-carriers) and over
45 years of age the incidence was 1-2%/year (vs. 0-3%/
year in non-carriers) (Table I).
There had been 18 recurrent events in ten of the 20
symptomatic carriers; none of them was taking oral
anticoagulants at the time of the second event. One
symptomatic non-carrier experienced four recurrent events
despite treatment with oral anticoagulants. The incidence of
first recurrence was 3-7%/year in carriers, which was 3-7
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Fig 1. Venous Ihrombosis-free survival curves in 92 carriers (lower
line, probands excluded) and 90 non-carners (upper line). The
difference in curves was significant (logrank test: P = 0-009).
times higher (95% CI: 0-5-29-9) than the incidence of
recurrence in non-carriers (1-0%/year).
The median age at first thrombosis for the 20 sympto-
matic relatives with the factor V Leiden mutation was
30 years (ränge, 16-75 years). This median age of onset
was equal in both sexes. The median age of onset for the five
non-carriers was 28 years (ränge, 23-54 years).
Effect of other risk factors
In none of the families was deficiency of protein C, protein S,
or anti-thrombin found. However, two of the 12 propositi
(16-7%) were heterozygous carriers of the recently described
20210 G to A prothrombin variant, i.e. they had a second
defect in combination with factor V Leiden (Poort et al,
1996). After exclusion of these two families with the
prothrombin 20210A variant in addition to factor V Leiden,
the thrombotic incidence rate in factor V Leiden carriers of
non carriers
Age (years)
Fig 2. Venous thrombosis-free survival curves in 36 carriers (lower
line, probands excluded) and 31 non-carriers (upper line) after
exclusion of second-degree relatives. The difference in curves was
significant (logrank test: P = 0-002).
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Table I. Incidence rates of deep venous thromboembohsm per year in carriers and non carners per age categoiy in thrombophilic lamihes
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0 05 (0-0 1)
0 3 (0-0 7)
0 3 (0-0 9)
0 15 (0-0 3)
1 Incidence rates are in percentage per yeais
the remaming ten famdies was 0 58%/year and was 0 17%/
year m non-carners (relative risk 3 4, 95% CI l 2-10 1)
Cox regression analysis revealed for the 12 famihes to have
a risk ratio of 3 5 (95% CI l 3-9 3) for factor V Leiden and
a risk ratio of 2 2 (95% CI 0 5-9 2) for the prothrombin
20210A vanant (multivanate analysis)
The distnbuüon of environmental risk factors in carners
and non-carners was very similar with the exception of
pregnancies the 47 female carners expenenced 100
pregnancies, while the 44 female non-carners expenenced
50 pregnancies Precipitatmg risk factors dunng or shortly
before the first event were present m 15 (75%) of the 20
carners and m three (60%) of the five non-carners with
thrombosis (Table II) Four of the 20 carners with
thrombosis expenenced their first episode post partum
Other risk iactors in carners were surgery, use of oral
contraceptives, pregnancy and immobihzation, m only five
carners (25%) was the first episode apparently spontaneous
Risk factors in the five non-carners with thrombosis were
surgery and pregnancy, two non-carriers expenenced a
spontaneous thrombotic event All carners expenenced, in
total, 244 episodes of surgery (n = 84), immobilization
(n = 60) or pregnancy (mcludmg puerpenum, n = 100)
and 12 of these episodes were comphcated by a venous
thrombotic event (4 9%), which was the case m l 6% of the
non-carriers (185 episodes were comphcated by three
thrombotic events) Eleven of the 18 recurrent events
(61%) m carners were apparently spontaneous
In Table III, rate ratlos are presented when the mam risk
factors were entered in a Poisson regression model In this
multivanate-adjusted model the strengest environmental
risk factor was pregnancy and puerpenum (rate ratio 37 7),
followed by surgery (rate ratio 14 1), immobilization (rate
ratio 8 9) and use of oral contraceptives (rate ratio 4 1) We
found a highly mcreased risk (mteraction under a multi-
phcaüve model) when factor V Leiden was combmed with
pregnancy and puerpenum, and only a moderate mcreased
risk (mteraction under an additive model) when factor V
Leiden was combmed with surgery As the thrombotic risk of
surgery was also high in non-carners, the jomt risk
estimates are high for all combmaüons of risk iactors with
factor V Leiden, with annual rates of 2-7%
DISCUSSION
We periormed a study on 182 members of 12 referred
iamihes with thrombophiha At the age of 50 years, 25% of
carners had expenenced at least one venous thrombotic
event (vs 7% m non-carners) The mcidence rate of deep
vein thrombosis (superficial thrombophlebitis excluded) in
carners is six times higher than the reported mcidence rate
for the general Dutch population (about 0 11%/year)
(Nordstrom et al, 1992, Briet et al, 1994, National Medical
Registration of the Foundation Information Centre for
Health Care, 1996) This mcidence rate oi 0 11%/year for
the general population is probably an overesümation äs
recurrences are mcluded Interesüngly m the famihes we
studied the mcidence among non-carners (0 17%/year,
Table II. Potential risk factors associated with the first venous thrombosis



















Probands excluded There were five spontaneous venous thrombotic events among carners and
two among non carriers
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Table III Adjusted rate idüos (95 /o CI) for thc mam potential nsk
lactors on venous thrombotic events for the 1S2 relatives







30(1 l 8 2 )
l 6 (l 3-2 1)
37 7 (13 9-101 7)
14 l (4 S 41 8)
4 l (l 1-15 1)
8 9 (l 9-41 1)
The rate ratios aie the risks of thiombosis m the piesence of the
nsk factor ai> compaied to its absence adjusted foi the othei iactois
m the model All vanables aie coded äs ycb/no age u, coded m
10 year mlervals
adjusted for the prothrombm G20210A allele) dlso exceeded
this population figure This mcreased mcidence of venous
thrombosis m non camers is probably caused by the
selection of famihes that die very prone to thrombosis m
which the presence of more than one defect may be
suspected (Lane et al 1996 Lensen et al 1996 Rosendaal
1997) We also thmk that the significant higher thrombotic
mcidence found m first-degree relatives äs compared with
second degree relatives (which is charactenstic m polygenic
mhentance) gives suppoit to the hypothesized presence ot
more co existing genetic defects and justifies furthei
research work mto this matter
Previously in a population-based case-control study on
venous thrombosis (Leiden Thrombophilia Study LETS
Rosendaal ei al 1995) among 471 unselected consecutive
patients with a flrst objectively confirmed deep vem
thrombosis (all younger than 70 years) and 471 unrelated
age- and sex matched controls we found an odds tatio for
heterozygosity of 7 3 The lower nsk latio of 3 7 for
heterozygosity we found in thrombophilic famihes with
factor V Leiden may be the result of the high mcidence of
venous thrombosis m non carriers and the difference in
study design
Considenng Tables I and II we thmk that the mimmally
higher thrombotic nsk found in carriers older than 45 years
äs compared with the 25-45 year gioup is caused by the
occurrence of many thrombotic events dunng pregnancy
and pueipenum or the use of oial contraceptives in the 25-
45 years group demonstrating their important role äs a
thiombogenic nsk factors in this age group
Recenlly Middeldorp U al (1998) presented their results
of a lamily study on factor V Leiden They investigated first-
degree family members of consecutive patients with venous
thromboembolism äs opposed to i eierred high-iisk famihes
m oui study They and Zoller U al (1994) found that 97 /o öl
cariiers were still iree of thrombosis at age 30 years We
found lhat 28% of carneis m thrombophilic tarmhes had
expenenced thrombosis at this age (Fig 2) The mcidence
rate for first-degree heterozygous family members younger
than 61 yeais of age was 0 9%/yeai moie lhan two times
the mcidence rate found by Middeldorp a al (1998) (0 4 X,/
year m both calculaüons follow up started at the age of
Factor V Leiden m Thrombophilic Famihes 943
15 years) These compansons emphasize that the estimated
nsk of thrombosis for carneis of factor V Leiden depends on
the mclusion critena and is much higher m selected and
refeired famihes than in lelatives of consecutive unselected
patients This is also illustrated by comparmg our data with
data from a study lecently performed by Simiom et al
(1999) They included relatives of unselected patients and
found an annual thrombotic mcidence of 0 28% m carriers
and 0 09% m non-carriers (rate ratio 2 8 95% CI l l 8 6)
(m first degiee relatives we found l 7% m carriers and 0 3%
in non camers resultmg in a doubled late ratio of 5 7 95%
CI 2 0 26 8) We recently found thrombotic incidences in
first-degree lelatives of 47 unselected consecutive patients
with a first venous thrombosis that were five times Iowei m
camers and three times lower m non-carriers than the
thrombotic incidences we found m the thrombophilic
lamilies Only one of these 47 lamilies (2%) met the
mclusion critena used in the current study (more than
one symptomatic lelative besides the proband) and 8% of
the first degiee relatives had expenenced a deep vem
thiombosis (äs Middeldorp et al 1998 found in their study
population Lensen et al 2000) vs 47% m the current study
This illustrates the role of a strong family history äs a
piobable nsk factor for venous thrombosis
The mclusion of thrombotic events that were not
objectively diagnosed (20%) could have led to an over-
estimation of the thrombotic mcidence As the possibility of
misclassification conceins only this fraction of all events
and äs the medical histoiy m these patients strongly
mdicated a deep venous thrombosis this cannot have
affected our figures matenally (after exclusion of the 20%
who were not objectively diagnosed we found similar nsk
estimates with wider confldence intervals)
Two years and 6 yeais after the fnst event 10% (two out
of 20) and 25% (five out of 20) of the symptomatic carriers
had expenenced a second event (superficial thiombophlebi
tis excluded) These high recuuence iisks m factor V Leiden
cairiers are similar to the results of previous studies from
the United States and Italy (Ridker U al 1995 Simiom et al
1997 Prandom et al 1998) The protective role of oral
anticoagulants is well illustrated m these 20 symptomatic
camers None of the eight camers who received oral
anticoagulant tieatment expenenced a recurrence while
ten of the 12 carriers who received no oral anticoagulant
treatment expenenced a recurrence
Remaikably two (16 7%) of the propositi had a combmed
defect l e factor V Leiden and the prothiombin G20210A
vanant This mutation has a population prevalence of about
2°/i and therefore it seems probable that the combination of
defects led to these patients becommg index patients (Poort
et al 1996) The elevated mcidence m non-carriers could
not be explamed by the presence of the prothrombin
G20210A vanant none of the relatives carrying only the
prothiombin G20210A vanant had expenenced a venous
thiombosis and the thrombotic mcidence rate in non
camers was even higher after exclusion of the two famihes
with the piothiombm G20210A vanant
We compaied our data with data from a study performed
by Allaart et al (1993) on similai selected thrombophilic
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famibes with heterozygous protein C deficiency (who were
also known to our centre) for thrombophiha work-up. Usmg
these data, we iound that the median of thrombotic
mcidence and recurrence rates were very similar for both
defects, which does not lend support to different thrombotic
nsks for protein C deficiency and factor V Leiden.
In conclusion, m climcal practice special attention should
be paid to young symptomatic mdividuals and their relatives
with a strong positive family history of venous thromboem-
bolism or a history of recurrent venous thrombosis who are
at risk, especially women who would like to use oral
contraceptives or who mtend to become pregnant. Identi-
fication of carners of factor V Leiden may be worthwhile m
these persons m order to discourage contraceptive pill use
among carners and to protect carners dunng pregnancies
agamst venous thrombosis However, data that such a
policy would be beneficial are lacking In addition, our data
are based on a study among selected families with
thrombophiha and should not be applied to screenmg of
other asymptomatic mdividuals (i.e. prior to prescnbmg oral
contraceptives). Finally, our data provide no grounds to
treat patients with factor V Leiden differently from patients
with heterozygous protein C deficiency However, consider-
ing the fact that the prevalence of factor V Leiden is at least
tenfold higher than the prevalence of all other known
genetic deficiencies, further prospective studies will be
needed to evaluate clinical policy.
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